Affimed Operating Margin 2014-2024 | AFMDQ
Current and historical operating margin for Affimed (AFMDQ) over the last 10 years. The current operating profit margin for Affimed as of September 30, 2024 is -7836.98%.
| Affimed Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2024-09-30 |
$0.00B |
$-0.08B |
0.00% |
| 2024-06-30 |
$0.00B |
$-0.09B |
-4350.00% |
| 2024-03-31 |
$0.00B |
$-0.10B |
-2550.00% |
| 2023-12-31 |
$0.01B |
$-0.12B |
-1277.78% |
| 2023-09-30 |
$0.02B |
$-0.12B |
-590.48% |
| 2023-06-30 |
$0.03B |
$-0.12B |
-341.18% |
| 2023-03-31 |
$0.04B |
$-0.11B |
-267.50% |
| 2022-12-31 |
$0.04B |
$-0.09B |
-209.09% |
| 2022-09-30 |
$0.04B |
$-0.09B |
-202.27% |
| 2022-06-30 |
$0.04B |
$-0.09B |
-235.90% |
| 2022-03-31 |
$0.04B |
$-0.09B |
-209.30% |
| 2021-12-31 |
$0.05B |
$-0.08B |
-158.33% |
| 2021-09-30 |
$0.05B |
$-0.06B |
-129.79% |
| 2021-06-30 |
$0.05B |
$-0.04B |
-85.71% |
| 2021-03-31 |
$0.04B |
$-0.03B |
-82.50% |
| 2020-12-31 |
$0.03B |
$-0.04B |
-121.88% |
| 2020-09-30 |
$0.03B |
$-0.04B |
-156.00% |
| 2020-06-30 |
$0.02B |
$-0.05B |
-333.33% |
| 2020-03-31 |
$0.02B |
$-0.05B |
-288.24% |
| 2019-12-31 |
$0.02B |
$-0.04B |
-154.17% |
| 2019-09-30 |
$0.05B |
$-0.01B |
-25.53% |
| 2019-06-30 |
$0.05B |
$-0.01B |
-26.67% |
| 2019-03-31 |
$0.04B |
$-0.01B |
-30.00% |
| 2018-12-31 |
$0.03B |
$-0.02B |
-82.14% |
| 2018-09-30 |
$0.00B |
$-0.04B |
-2100.00% |
| 2018-06-30 |
$0.00B |
$-0.04B |
-1233.33% |
| 2018-03-31 |
$0.00B |
$-0.03B |
-825.00% |
| 2017-12-31 |
$0.00B |
$-0.03B |
-1033.33% |
| 2017-09-30 |
$0.00B |
$-0.03B |
-1033.33% |
| 2017-06-30 |
$0.00B |
$-0.03B |
-1100.00% |
| 2017-03-31 |
$0.00B |
$-0.04B |
-900.00% |
| 2016-12-31 |
$0.01B |
$-0.04B |
-600.00% |
| 2016-09-30 |
$0.01B |
$-0.04B |
-528.57% |
| 2016-06-30 |
$0.01B |
$-0.03B |
-485.71% |
| 2016-03-31 |
$0.01B |
$-0.03B |
-428.57% |
| 2015-12-31 |
$0.01B |
$-0.03B |
-312.50% |
| 2015-09-30 |
$0.01B |
$-0.02B |
-283.33% |
| 2015-06-30 |
$0.01B |
$-0.01B |
-142.86% |
| 2015-03-31 |
$0.01B |
$0.00B |
-50.00% |
| 2014-12-31 |
$0.00B |
$0.00B |
25.00% |
| 2014-09-30 |
$0.00B |
$0.00B |
25.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
